73619-9
Iclaprim [Susceptibility] by Minimum inhibitory concentration (MIC)
Active
Part Description
LP172566-4 Iclaprim
Iclaprim, codenamed AR-100 and RO-48-2622, is a diaminopyrimidine dihydrofolate reductase inhibitor being developed for the treatment of complicated skin and soft tissue infections caused by antibiotic-resistant bacteria. It is structurally related to trimethoprim. In Phase III clinical trials, intravenously-administered iclaprim was found to be as effective as and better tolerated than linezolid in people with skin and soft tissue infections, many caused by methicillin-resistant Staphylococcus aureus (MRSA). In vitro, iclaprim is highly active against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria. A new drug application for iclaprim was filed with the U.S. Food and Drug Administration in March 2008, and a marketing authorisation application (MAA) was accepted by the European Medicines Agency on August 21, 2008. Phase II clinical trials are being conducted to assess whether iclaprim can be taken by mouth as well as intravenously and whether it is effective for the treatment of hospital-acquired pneumonia. Iclaprim has been granted fast track status by the FDA
Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
Source: Wikipedia, Wikipedia
Fully-Specified Name
- Component
- Iclaprim
- Property
- Susc
- Time
- Pt
- System
- Isolate
- Scale
- OrdQn
- Method
- MIC
Additional Names
- Short Name
- Iclaprim Islt MIC
- Display Name
- Iclaprim MIC [Susc]
- Consumer Name Alpha Get Info
- Susceptibility to Iclaprim
Basic Attributes
- Class
- ABXBACT
- Type
- Laboratory
- First Released
- Version 2.44
- Last Updated
- Version 2.44
- Order vs. Observation
- Observation
Member of these Panels
LOINC | Long Common Name |
---|---|
50545-3 | Bacterial susceptibility panel by Minimum inhibitory concentration (MIC) |
Member of these Groups Get Info
LOINC Group | Group Name |
---|---|
LG41455-3 | IclaprimSusc| |
Language Variants Get Info
Tag | Language | Translation |
---|---|---|
de-DE | German (Germany) | Iclaprim: |
es-ES | Spanish (Spain) | Iclaprim: |
es-MX | Spanish (Mexico) | Iclaprim: |
fr-FR | French (France) | Iclaprime: |
it-IT | Italian (Italy) | Iclaprim: Synonyms: Concentrazione minima inibitoria Punto nel tempo (episodio) Sensibilità (microrganismi) Suscettibilità agli antibiotici |
nl-NL | Dutch (Netherlands) | iclaprim: Synonyms: MIC |
pt-BR | Portuguese (Brazil) | Iclaprim: |
ru-RU | Russian (Russian Federation) | Иклаприм: Synonyms: Минимальная ингибирующая концентрация (МИК) Порядковый или Количественный Точка во времени; |
tr-TR | Turkish (Turkey) | Iklaprim: |
zh-CN | Chinese (China) | 艾拉普林: Synonyms: 分离物; |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=73619-9
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright